New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

ETF IssuersInvescoPBE
PBE

Invesco Dynamic Biotechnology & Genome ETF

The PBE Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: Dynamic Biotech & Genome Intellidex Index. The PBE ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

$92.76
+$1.6 (+1.80%) yesterday
1:30 PM 08/07/26 Closed
1D price range
$91.48$92.76
52W price range
$64.95$93.28
YTD Perf.
+14.30%
YTD Flows
Annualized volatility
Fund AuM
€314M
Share class AuM
€314M
TTM Yield
Tracking Error
Tracking Difference
ISIN
US46137V7872
TER
0.58%
Inception date
6/23/2005
Issuer
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Aug 7, 2026
-5%0%5%10%15%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
100.00%
Latest PBE news

No content available for this fund

FAQ about PBE

PBE is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.
PBE tracks the Dynamic Biotech & Genome Intellidex TR Index - USD, through a full replication replication method.
PBE carries a total expense ratio (TER) of 0.58%, indicating the annual cost for holding the fund.
PBE was introduced to the market on June 23, 2005. It trades on United States
Invesco Dynamic Biotechnology & Genome ETF, PBE, is provided by Invesco. Learn more about Invesco here.
PBE oversees €314M in assets as of August 7, 2026.
PBE follows a distributing dividend policy, meaning it pays out income to investors. As of August 7, 2026, its 12-month trailing yield was 1.67%.
As of June 30, 2026, PBE has significant geographic allocations in USA and Netherlands.
As of June 30, 2026, PBE focuses largely on Healthcare.
As of June 30, 2026, PBE holds 30 positions in its portfolio, with 60.29% of assets concentrated in its top 15 holdings.
As of June 30, 2026, PBE top three holdings include Vertex Pharmaceuticals, Inc., Biogen, Inc. and Amgen, Inc..
The base currency of PBE is USD.
Data as of 06/30/26
Vertex Pharmaceuticals, Inc.
5.12%
Biogen, Inc.
5.08%
Amgen, Inc.
4.84%
Royalty Pharma Plc
4.74%
Regeneron Pharmaceuticals, Inc.
4.53%
Alnylam Pharmaceuticals, Inc.
4.48%
Gilead Sciences, Inc.
4.34%
United Therapeutics Corp.
4.26%
Bio-Techne Corp.
3.67%
Veracyte, Inc.
3.39%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight